Skip navigation

Earnings roundup: WellPoint, Eli Lilly

Among the earnings stories for Wednesday, July 24, from AP Business News Full story

Eli Lilly earnings beat

   John Lechleiter, chairman, president & CEO, Eli Lilly, says they overcame the loss of patents by growing the sales of other products. The company's focus is beginning to turn to autoimmune diseases.

Lilly beats forecast, helped by drug soon to face generics

(Reuters) - Eli Lilly and Co reported higher-than-expected quarterly earnings, helped by cost cuts and strong sales growth of Cymbalta, a depression treatment that will soon lose patent protection, and the drugmaker raised its full-year profit forecast. Full story

Lilly beats forecast, helped by drugs soon to face generics

(Reuters) - Eli Lilly and Co <LLY.N> reported higher-than-expected quarterly earnings, helped by cost cuts and strong sales growth of depression and impotence treatments that will soon lose patent protection, and the drugmaker raised its full-year profit forecast. Full story

Eli Lilly to freeze employee base pay ahead of generic onslaught

NEW YORK (Reuters) - U.S. drugmaker Eli Lilly & Co <LLY.N>, which expects to lose about 20 percent of its global revenue next year due to the expiration of key drug patents, is suspending base pay increases for most employees in 2014 to cut costs. Full story

J&J studying deaths of two patients on long-acting Zyprexa

(Reuters) - The U.S. Food and Drug Administration on Tuesday said it was investigating deaths of two patients who died following injections with Eli Lilly and Co's long-acting treatment for schizophrenia, called Zyprexa Relprevv. Full story

Sponsored Links

Articles

Eli Lilly to Take Over Development of Diabetes Drug

Lilly CEO Lechleiter to undergo surgery for dilated aorta

Eli Lilly CEO says company keeping animal health business

Video

  Eli Lilly CEO on the Future of Big Pharma

John Lechleiter, chairman, president & CEO of Eli Lilly, discusses which new drugs are in the company's pipeline as its stock nears 52-week highs.

advertisement | ad info

Related Photos

John Lechleiter, chairman, president, and chief executive officer of Eli Lilly and Company, speaks at the Reuters Health Summit in New York
John Lechleiter, chairman, president, and chief executive officer of Eli Lilly and Company, speaks at the Reuters Health Summit in New York

John Lechleiter, chairman, president, and chief executive officer of Eli Lilly and Company, speaks at the Reuters Health Summit in New York, November 9, 2009. REUTERS/Brendan McDermid